Haemophilus influenzae Type b Reemergence after Combination Immunization
Nik G. Johnson*, Jens U. Ruggeberg*, Gail F. Balfour*, Y. Chen Lee†, Helen Liddy‡, Diane Irving‡, Joanna Sheldon‡, Mary P.E. Slack§, Andrew J. Pollard†, and Paul T. Heath*
Author affiliations: *St George's University of London, London, United Kingdom; †University of Oxford, Oxford, United Kingdom; ‡St. George's Hospital, London, United Kingdom; §Health Protection Agency Centre for Infections, London, United Kingdom
Figure 2. Anti-polyribosyl-ribitol phosphate antibody concentrations in 2- to 4-year-old children, according to number of doses of acellular pertussis containing Haemophilus influenzae type b combination vaccines received in infancy. Proportion achieving different concentrations is shown.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.